Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 21077P108 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| MPM BioImpact LLC 13G/A Amendment 2 | 1.4% |
8/14/2026
Event 6/30/2026
|
|
| Blue Owl Capital Holdings LP 13G/A Amendment 3 | 3.2% |
8/12/2026
Event 6/30/2026
|
|
|
Octagon Capital Advisors LP
13G/A
Amendment 1
|
3.3% |
7/31/2026
Event 6/30/2026
|
|
| Octagon Capital Advisors LP | 3.3% | ||
| Octagon Investments Master Fund LP | 3.3% | ||
| Ting Jia | 3.3% | ||
| BlackRock, Inc. 13G | 6.7% |
7/27/2026
Event 6/30/2026
|
|
|
Great Point Partners, LLC
13G/A
Amendment 7
|
2.4% |
5/15/2026
Event 3/31/2026
|
|
| Great Point Partners, LLC | 2.4% | ||
| Dr. Jeffrey R. Jay, M.D. | 2.4% | ||
| Ms. Lillian Nordahl | 2.4% | ||
|
Octagon Capital Advisors LP
13G
|
5.7% |
5/14/2026
Event 3/31/2026
|
|
| Octagon Capital Advisors LP | 5.7% | ||
| Octagon Investments Master Fund LP | 5.7% | ||
| Ting Jia | 5.7% | ||
| Blue Owl Capital Holdings LP 13G/A Amendment 2 | 5.5% |
5/14/2026
Event 3/31/2026
|
|
|
Avidity Partners Management LP
13G/A
Amendment 5
|
8.7% |
5/12/2026
Event 3/31/2026
|
|
| Avidity Partners Management LP | 8.7% | ||
| Avidity Partners Management (GP) LLC | 8.7% | ||
| Avidity Capital Partners Fund (GP) LP | 8.7% | ||
| Avidity Capital Partners (GP) LLC | 8.7% | ||
| Avidity Private Master Fund I LP | 7.7% | ||
| Michael Gregory | 8.7% | ||
|
Soleus Capital Master Fund, L.P.
13G/A
Amendment 1
|
7.6% |
5/8/2026
Event 3/31/2026
|
|
| Soleus Capital Master Fund, L.P. | 7.6% | ||
| Soleus Capital, LLC | 7.6% | ||
| Soleus Capital Group, LLC | 7.6% | ||
| Soleus Capital Management, L.P. | 7.6% | ||
| Soleus GP, LLC | 7.6% | ||
| Guy Levy | 7.6% | ||
| MPM BioImpact LLC 13G/A Amendment 1 | 11.6% |
2/17/2026
Event 12/31/2025
|
|
|
Great Point Partners, LLC
13G/A
Amendment 6
|
5.1% |
2/17/2026
Event 12/31/2025
|
|
| Great Point Partners, LLC | 5.1% | ||
| Dr. Jeffrey R. Jay, M.D. | 5.1% | ||
| Ms. Lillian Nordahl | 5.1% | ||
|
Soleus Capital Master Fund, L.P.
13G
|
5.2% |
2/3/2026
Event 2/2/2026
|
|
| Soleus Capital Master Fund, L.P. | 5.2% | ||
| Soleus Capital, LLC | 5.2% | ||
| Soleus Capital Group, LLC | 5.2% | ||
| Soleus Capital Management, L.P. | 5.2% | ||
| Soleus GP, LLC | 5.2% | ||
| Guy Levy | 5.2% | ||
|
Great Point Partners, LLC
13G/A
Amendment 5
|
5.2% |
11/14/2025
Event 9/30/2025
|
|
| Great Point Partners, LLC | 5.2% | ||
| Dr. Jeffrey R. Jay, M.D. | 5.2% | ||
| Ms. Lillian Nordahl | 5.2% | ||
|
Avidity Partners Management LP
13G/A
Amendment 4
|
9.9%
Checked 5% or less
|
11/14/2025
Event 9/30/2025
|
|
| Avidity Partners Management LP | 9.9% | ||
| Avidity Partners Management (GP) LLC | 9.9% | ||
| Avidity Capital Partners Fund (GP) LP | 9.9% | ||
| Avidity Capital Partners (GP) LLC | 9.9% | ||
| Avidity Master Fund LP | 4.9% | ||
| Avidity Private Master Fund I LP | 8.2% | ||
| Avidity Private Master Fund I LP | 8.2% | ||
| Michael Gregory | 9.9% | ||
|
Great Point Partners, LLC
13G/A
Amendment 4
|
5.2% |
8/14/2025
Event 6/30/2025
|
|
| Great Point Partners, LLC | 5.2% | ||
| Dr. Jeffrey R. Jay, M.D. | 5.2% | ||
| Ms. Lillian Nordahl | 5.2% | ||
|
Avidity Partners Management LP
13G/A
Amendment 3
|
9.9% |
8/14/2025
Event 6/30/2025
|
|
| Avidity Partners Management LP | 9.9% | ||
| Avidity Partners Management (GP) LLC | 9.9% | ||
| Avidity Capital Partners Fund (GP) LP | 9.9% | ||
| Avidity Capital Partners (GP) LLC | 9.9% | ||
| Avidity Master Fund LP | 5.6% | ||
| Avidity Private Master Fund I LP | 8.4% | ||
| Michael Gregory | 9.9% | ||
|
Great Point Partners, LLC
13G/A
Amendment 3
|
5.2% |
5/15/2025
Event 3/31/2025
|
|
| Great Point Partners, LLC | 5.2% | ||
| Dr. Jeffrey R. Jay, M.D. | 5.2% | ||
| Ms. Lillian Nordahl | 5.2% | ||
|
Deep Track Capital, LP
13G/A
Amendment 1
|
8.3% |
5/15/2025
Event 3/31/2025
|
|
| Deep Track Capital, LP | 8.3% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 8.3% | ||
| David Kroin | 8.3% | ||
|
Franklin Resources, Inc.
13G/A
Amendment 1
|
4.5% |
5/9/2025
Event 3/31/2025
|
|
| Franklin Resources, Inc. | 4.5% | ||
| Charles B. Johnson | 0% | ||
| Rupert H. Johnson, Jr. | 0% | ||
| Opaleye Management Inc. 13G/A Amendment 1 | 0% |
2/14/2025
Event 12/31/2024
|
|
|
Great Point Partners, LLC
13G/A
Amendment 2
|
6.3% |
2/14/2025
Event 12/31/2024
|
|
| Great Point Partners, LLC | 6.3% | ||
| Dr. Jeffrey R. Jay, M.D. | 6.3% | ||
| Ms. Lillian Nordahl | 6.3% | ||
| Blue Owl Capital Holdings LP 13G/A Amendment 1 | 8.5% |
2/14/2025
Event 12/31/2024
|
|
|
Avidity Partners Management LP
13G/A
Amendment 2
|
9.9%
Checked 5% or less
|
2/14/2025
Event 12/31/2024
|
|
| Avidity Partners Management LP | 9.9% | ||
| Avidity Partners Management (GP) LLC | 9.9% | ||
| Avidity Capital Partners Fund (GP) LP | 9.9% | ||
| Avidity Capital Partners (GP) LLC | 9.9% | ||
| Avidity Master Fund LP | 6.7% | ||
| Avidity Private Master Fund I LP | 9.9% | ||
| David Witzke | 0% | ||
| Michael Gregory | 9.9% | ||
|
Lehr Martin A.
13G/A
Amendment 2
|
2.1% |
2/12/2025
Event 12/31/2024
|
|
| Martin Lehr | 2.1% | ||
| Martin Lehr 2000 Trust | 1.1% | ||
| Ellyn Lehr | 1.1% | ||
|
Franklin Resources, Inc.
13G
|
5.3% |
1/27/2025
Event 12/31/2024
|
|
| Franklin Resources, Inc. | 5.3% | ||
| Charles B. Johnson | 0% | ||
| Rupert H. Johnson, Jr. | 0% | ||
| Franklin Advisers, Inc. | 5.3% | ||
| MPM BioImpact LLC 13G | 16.4% |
1/8/2025
Event 12/31/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 6.98 k | $2.10 k |
| 2026 Q2 | 79 | 62.8 M | $34.8 M |
| 2026 Q1 | 63 | 79.3 M | $206 M |
| 2025 Q4 | 44 | 65.3 M | $96.0 M |
| 2025 Q3 | 37 | 69.0 M | $66.8 M |
| 2025 Q2 | 40 | 68.6 M | $45.0 M |
| 2025 Q1 | 43 | 71.4 M | $43.7 M |
| 2024 Q4 | 53 | 72.8 M | $76.4 M |
| 2024 Q3 | 44 | 56.7 M | $111 M |
| 2024 Q2 | 36 | 59.0 M | $118 M |
| 2024 Q1 | 27 | 3.94 M | $5.43 M |
| 2023 Q4 | 26 | 3.56 M | $4.02 M |
| 2023 Q3 | 24 | 2.58 M | $3.89 M |
| 2023 Q2 | 23 | 2.24 M | $3.58 M |
| 2023 Q1 | 23 | 1.29 M | $723 k |
| 2022 Q4 | 26 | 3.92 M | $2.57 M |
| 2022 Q3 | 25 | 4.13 M | $4.59 M |
| 2022 Q2 | 21 | 3.64 M | $6.32 M |
| 2022 Q1 | 17 | 2.90 M | $6.30 M |
| 2021 Q4 | 20 | 3.55 M | $9.44 M |